$GOVX: NEWS--- Leveraging GeoVax's Vaccine Expe
Post# of 107098
(Total Views: 370)
Posted On: 09/09/2019 8:45:36 AM
$GOVX: NEWS---
Leveraging GeoVax's Vaccine Expertise To Take On Cancer
ATLANTA, GA, September 9, 2019 – GeoVax Labs, Inc. (OTCQB:GOVX), a biotechnology company developing human immunotherapies and vaccines has historically been associated with the development of vaccines against infectious diseases. The company is now leveraging the knowledge and expertise it has validated in infectious diseases and expanding the applicability of MVA-VLP into immuno-oncology (IO) with highly promising results.
The company's Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform technology has been successfully validated in multiple development programs, including HIV, Zika, and Hemorrhagic Fevers such as Ebola, Marburg and Lassa. However, the advancement of these critical programs into clinical development has been challenging. GeoVax is now leveraging the knowledge and expertise it has validated in infectious diseases and expanding the applicability of MVA-VLP into immuno-oncology (IO) with highly promising results.
The safety and efficacy of the MVA platform are well recognized and accepted. Originally developed as a safer vaccine against smallpox in the 1950s, MVA now serves as validated vector delivery foundation technology on which the development of new vaccine candidates are built. MVA vaccines have been tested on over 120,000 people, demonstrating outstanding safety, especially in immunocompromised individuals. Importantly, MVA vaccines have been found immunogenic and protective in various preclinical models and human clinical trials, including in HIV, HBV, MERS, avian influenza virus H5N1, Ebola, Zika, and Mycobacterium tuberculosis (Volz & Sutter, Adv. Virus Res, 2017).
Scientists at GeoVax have been able to capitalize and build on the MVA platform by utilizing recombinant DNA technology to incorporate Virus-Like Particles (VLPs) into the MVA delivery construct. VLPs are non-infectious portions of the pathogenic virus or bacteria. Often they are truncated forms of a surface protein or receptor. They are big enough to elicit an immune response and confer immunity, but have no risk of causing infection or harm; this is in contrast to weakened (attenuated) or killed forms of the virus, like the current influenza virus vaccines. GeoVax has conducted six human trials of the MVA-VLP platform in more than 500 subjects with no serious adverse reactions. The GeoVax MVA-VLP platform and approach has been well documented and validated in the multitude of trials........
https://geovax.reportablenews.com/pr/leveragi...-on-cancer
Leveraging GeoVax's Vaccine Expertise To Take On Cancer
ATLANTA, GA, September 9, 2019 – GeoVax Labs, Inc. (OTCQB:GOVX), a biotechnology company developing human immunotherapies and vaccines has historically been associated with the development of vaccines against infectious diseases. The company is now leveraging the knowledge and expertise it has validated in infectious diseases and expanding the applicability of MVA-VLP into immuno-oncology (IO) with highly promising results.
The company's Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform technology has been successfully validated in multiple development programs, including HIV, Zika, and Hemorrhagic Fevers such as Ebola, Marburg and Lassa. However, the advancement of these critical programs into clinical development has been challenging. GeoVax is now leveraging the knowledge and expertise it has validated in infectious diseases and expanding the applicability of MVA-VLP into immuno-oncology (IO) with highly promising results.
The safety and efficacy of the MVA platform are well recognized and accepted. Originally developed as a safer vaccine against smallpox in the 1950s, MVA now serves as validated vector delivery foundation technology on which the development of new vaccine candidates are built. MVA vaccines have been tested on over 120,000 people, demonstrating outstanding safety, especially in immunocompromised individuals. Importantly, MVA vaccines have been found immunogenic and protective in various preclinical models and human clinical trials, including in HIV, HBV, MERS, avian influenza virus H5N1, Ebola, Zika, and Mycobacterium tuberculosis (Volz & Sutter, Adv. Virus Res, 2017).
Scientists at GeoVax have been able to capitalize and build on the MVA platform by utilizing recombinant DNA technology to incorporate Virus-Like Particles (VLPs) into the MVA delivery construct. VLPs are non-infectious portions of the pathogenic virus or bacteria. Often they are truncated forms of a surface protein or receptor. They are big enough to elicit an immune response and confer immunity, but have no risk of causing infection or harm; this is in contrast to weakened (attenuated) or killed forms of the virus, like the current influenza virus vaccines. GeoVax has conducted six human trials of the MVA-VLP platform in more than 500 subjects with no serious adverse reactions. The GeoVax MVA-VLP platform and approach has been well documented and validated in the multitude of trials........
https://geovax.reportablenews.com/pr/leveragi...-on-cancer
(0)
(0)
Sojourner here following God, obeying God, and cleaving to Him. The journey is onward.